Should you buy Zoetis (ZTS)?
Updated
Zoetis is a high-quality animal health business with 68% return on equity, 28% net margins, and a 3-for-4 earnings beat streak — but an extraordinary put-to-call ratio of 18.50, a confirmed death-cross technical pattern, and heavy concentration in companion animal products (70%) create a profile where the long-term quality case is strong but the near-term setup is unusually risky.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Engine methodology range
Range computation requires sufficient peer-comparable data; available for tickers with peer_count ≥3.
What the engine is tracking
| Pillar | Expectation | Trend |
|---|---|---|
Zoetis achieves a 68% return on equity, 28% net margins, and a quality score of 8.3 — ranking in the top decile of its peer group on quality — with a Piotroski F-Score of 8/9, reflecting the durable pricing power of branded animal health products. Quality breakdown | Return on equity remains above 50% and net margins stay above 22% over the next 4 quarters, confirming the quality advantage is structural. | →Stable |
| CounterFree cash flow covers only 67% of net income — a quality warning — suggesting that reported margins may not fully translate into distributable cash due to working capital or capital spending requirements. | ||
Companion animal products account for 70% of revenue, representing a high product-concentration risk — any regulatory setback, pricing pressure from generics, or shift in veterinary spending patterns would disproportionately impact the business. Bear case | Livestock or international product revenue grows to represent more than 35% of total revenue within 18 months, reducing companion animal concentration below 65%. | →Stable |
| CounterCompanion animal spending has shown exceptional resilience through economic downturns as pet ownership and veterinary care spending have structurally increased; the concentration reflects a highly attractive end market. | ||
Zoetis has a put-to-call options ratio of 18.50 — one of the highest readings observable in large-cap healthcare — indicating an extraordinary level of downside protection being purchased relative to upside calls, which historically signals institutional concern about a specific near-term risk event. Risk breakdown | Put-to-call ratio falls below 5.0 within 3 months, declining by more than 70% from the current extreme 18.50 level, as the options market concern resolves. | →Stable |
| CounterAn extreme put-to-call ratio can reflect concentrated options hedging by a small number of large institutional holders rather than broad market bearishness; the signal may overstate the genuine directional view. | ||
Zoetis achieves a 68% return on equity, 28% net margins, and a quality score of 8.3 — ranking in the top decile of its peer group on quality — with a Piotroski F-Score of 8/9, reflecting the durable pricing power of branded animal health products.
→Stable- Expectation
- Return on equity remains above 50% and net margins stay above 22% over the next 4 quarters, confirming the quality advantage is structural.
CounterFree cash flow covers only 67% of net income — a quality warning — suggesting that reported margins may not fully translate into distributable cash due to working capital or capital spending requirements.
Companion animal products account for 70% of revenue, representing a high product-concentration risk — any regulatory setback, pricing pressure from generics, or shift in veterinary spending patterns would disproportionately impact the business.
→Stable- Expectation
- Livestock or international product revenue grows to represent more than 35% of total revenue within 18 months, reducing companion animal concentration below 65%.
CounterCompanion animal spending has shown exceptional resilience through economic downturns as pet ownership and veterinary care spending have structurally increased; the concentration reflects a highly attractive end market.
Zoetis has a put-to-call options ratio of 18.50 — one of the highest readings observable in large-cap healthcare — indicating an extraordinary level of downside protection being purchased relative to upside calls, which historically signals institutional concern about a specific near-term risk event.
→Stable- Expectation
- Put-to-call ratio falls below 5.0 within 3 months, declining by more than 70% from the current extreme 18.50 level, as the options market concern resolves.
CounterAn extreme put-to-call ratio can reflect concentrated options hedging by a small number of large institutional holders rather than broad market bearishness; the signal may overstate the genuine directional view.
▸ Show 1 more pillar▾ Show fewer
The stock is in a confirmed death-cross pattern with the 200-day moving average declining at -7.7% per 30 days and the 52-week position at its lowest point, despite a recovering MACD and RSI at 49 — the technical structure is inconsistent and the downtrend has not yet reversed.
→Stable- Expectation
- The 200-day moving average slope improves to flat or positive within 6 months, and the stock price rises above the 200-day average for at least 10 consecutive trading days.
CounterThe 40% analyst upside to $112.13 from the current $79.95 suggests the market has materially overshot to the downside; an improving MACD at the current low RSI may signal the death-cross exhaustion point.
→ Full pillar scorecard with all 4 pillars + per-dimension breakdown
When this thesis breaks
Falsifiable conditions per pillar — any one trip warrants review independent of price action. Engine-derived; not personalized advice.
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Zoetis has a put-to-call options ratio of 18.50 — one of the highest readings observable in large-cap healthcare — indicating an extraordinary level of downside protection being purchased relative to upside calls, which historically signals institutional concern about a specific near-term risk event.
Trip ifPut-to-call ratio rises above 25.0, exceeding the current extreme 18.50 level, indicating options market concern is intensifying.
- P2Zoetis achieves a 68% return on equity, 28% net margins, and a quality score of 8.3 — ranking in the top decile of its peer group on quality — with a Piotroski F-Score of 8/9, reflecting the durable pricing power of branded animal health products.
Trip ifReturn on equity falls below 40% for 2 consecutive quarters, declining more than 40% from the current 68% level.
- P3Companion animal products account for 70% of revenue, representing a high product-concentration risk — any regulatory setback, pricing pressure from generics, or shift in veterinary spending patterns would disproportionately impact the business.
Trip ifCompanion animal revenue declines by more than 10% year-over-year for 2 consecutive quarters.
- P4The stock is in a confirmed death-cross pattern with the 200-day moving average declining at -7.7% per 30 days and the 52-week position at its lowest point, despite a recovering MACD and RSI at 49 — the technical structure is inconsistent and the downtrend has not yet reversed.
Trip ifPrice drops below $72, declining more than 10% below the current $79.95, while the 200-day MA slope remains below -5% per 30 days.
How the engine reached this verdict
TrendMatrix's engine output for Zoetis Inc. (ZTS) is SELL_IF_HOLDING with medium conviction, score 5.9/10 at $79.12. The F-path SELL output reflects an overall score of 4.4 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. Asymmetry R:R of 6.71 is supplementary context, not the trigger.
SELL output reflects multiple gate failures; recovery requires a confluence of those gates re-clearing, not a single dimension move.
On the bull side: Strong earnings beat streak (3/4); High-quality business; Attractive valuation. On the bear side: Concentration risk — Geographic: United States (54.0%); Concentration risk — Product: companion animal products (70.0%); Leverage penalty (D/E 2.9): -1.5.
The engine's exit framework anchors to a tactical sell band near $79.12, with structural invalidation at $74.45. The asymmetric R:R against a reversal hypothesis is 6.66 — the upside scenario exists, but it requires multiple structural gates to flip; the downside scenario requires only one more disappointment. The engine's sizing output: 0.5% of portfolio at this asymmetry level (none-conviction tier).
For the full 10-dimension breakdown + V9 gate detail: Why TrendMatrix rates ZTS — 10-dimension breakdown →
Bull case
- ▸Strong earnings beat streak (3/4)
- ▸High-quality business
- ▸Attractive valuation
Bear case
- ▸Concentration risk — Geographic: United States (54.0%)
- ▸Concentration risk — Product: companion animal products (70.0%)
- ▸Leverage penalty (D/E 2.9): -1.5